Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.

• PubMed
Siegel RL, Miller KD, Wagle NS, Cancer statistics, 2023. CA Cancer J Clin 2023;73:17–48.)| false
• Search Google Scholar
• Export Citation

Barnholtz-Sloan J, Patel N, Rollison D, et al. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:1129–1138.

• PubMed
Barnholtz-Sloan J, Patel N, Rollison D, Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:1129–1138.)| false
• Search Google Scholar
• Export Citation

Wang SS, Carreon JD, Gomez SL, et al. Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004. Cancer 2010;116:949–956.

• PubMed
Wang SS, Carreon JD, Gomez SL, Cervical cancer incidence among 6 Asian ethnic groups in the United States, 1996 through 2004. Cancer 2010;116:949–956.)| false
• Search Google Scholar
• Export Citation

Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711–1742.

• PubMed
Howe HL, Wu X, Ries LA, Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711–1742.)| false
• Search Google Scholar
• Export Citation

Sherman ME, Wang SS, Carreon J, et al. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005;103:1258–1264.

• PubMed
Sherman ME, Wang SS, Carreon J, Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005;103:1258–1264.)| false
• Search Google Scholar
• Export Citation

Global Cancer Observatory. Cancer over time. Accessed October 25, 2023. Available at: https://gco.iarc.fr/overtime/en/dataviz/tables?hide_tab_age_specific_numbers=1&mode=population&years=2012

• PubMed
Global Cancer Observatory. Cancer over time. Accessed October 25, 2023. Available at: https://gco.iarc.fr/overtime/en/dataviz/tables?hide_tab_age_specific_numbers=1&mode=population&years=2012)| false
• Search Google Scholar
• Export Citation

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.

• PubMed
Parkin DM, Bray F, Ferlay J, Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.)| false
• Search Google Scholar
• Export Citation

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–2150.

• PubMed
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–2150.)| false
• Search Google Scholar
• Export Citation

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.

• PubMed
Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69–90.)| false
• Search Google Scholar
• Export Citation

Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677–686.

• PubMed
Bray F, Loos AH, McCarron P, Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677–686.)| false
• Search Google Scholar
• Export Citation

Watson M, Saraiya M, Benard V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008;113(10 Suppl):2855–2864.

• PubMed
Watson M, Saraiya M, Benard V, Burden of cervical cancer in the United States, 1998-2003. Cancer 2008;113(10 Suppl):2855–2864.)| false
• Search Google Scholar
• Export Citation

de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8:e180–190.

• PubMed
de Martel C, Georges D, Bray F, Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8:e180–190.)| false
• Search Google Scholar
• Export Citation

Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191–2199.

• PubMed
Bray F, Carstensen B, Møller H, Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191–2199.)| false
• Search Google Scholar
• Export Citation

Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004;100:1035–1044.

• PubMed
Wang SS, Sherman ME, Hildesheim A, Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004;100:1035–1044.)| false
• Search Google Scholar
• Export Citation

Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303–315.

• PubMed
Castellsagué X, Díaz M, de Sanjosé S, Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303–315.)| false
• Search Google Scholar
• Export Citation

Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009;125:525–529.

• PubMed
Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009;125:525–529.)| false
• Search Google Scholar
• Export Citation

Stolnicu S, Barsan I, Hoang L, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 2018;42:214–226.

• PubMed
Stolnicu S, Barsan I, Hoang L, International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 2018;42:214–226.)| false
• Search Google Scholar
• Export Citation

Kjær SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478–1488.

• PubMed
Kjær SK, Frederiksen K, Munk C, Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478–1488.)| false
• Search Google Scholar
• Export Citation

Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315–324.

• PubMed
Rodríguez AC, Schiffman M, Herrero R, Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315–324.)| false
• Search Google Scholar
• Export Citation

Dahlström LA, Ylitalo N, Sundström K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010;127:1923–1930.

• PubMed
Dahlström LA, Ylitalo N, Sundström K, Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010;127:1923–1930.)| false
• Search Google Scholar
• Export Citation

Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016;2:16086.

• PubMed
Schiffman M, Doorbar J, Wentzensen N, Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016;2:16086.)| false
• Search Google Scholar
• Export Citation

Burk RD, Chen Z, Saller C, et al. Integrated genomic and molecular characterization of cervical cancer. Nature 2017;543:378–384.

• PubMed
Burk RD, Chen Z, Saller C, Integrated genomic and molecular characterization of cervical cancer. Nature 2017;543:378–384.)| false
• Search Google Scholar
• Export Citation

Höhn AK, Brambs CE, Hiller GGR, et al. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 2021;81:1145–1153.

• PubMed
Höhn AK, Brambs CE, Hiller GGR, 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd 2021;81:1145–1153.)| false
• Search Google Scholar
• Export Citation

Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154–1161.

• PubMed
Keys HM, Bundy BN, Stehman FB, Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154–1161.)| false
• Search Google Scholar
• Export Citation

Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137–1143.

• PubMed
Morris M, Eifel PJ, Lu J, Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137–1143.)| false
• Search Google Scholar
• Export Citation

Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606–1613.

• PubMed
Peters WA, Liu PY, Barrett RJ, Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606–1613.)| false
• Search Google Scholar
• Export Citation

Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339–1348.

• PubMed
Whitney CW, Sause W, Bundy BN, Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339–1348.)| false
• Search Google Scholar
• Export Citation

Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–1153.

• PubMed
Rose PG, Bundy BN, Watkins EB, Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–1153.)| false
• Search Google Scholar
• Export Citation

Thomas GM. Improved treatment for cervical cancer—concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340:1198–1200.

• PubMed
Thomas GM. Improved treatment for cervical cancer—concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340:1198–1200.)| false
• Search Google Scholar
• Export Citation

Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2804–2810.

• PubMed
Rose PG, Ali S, Watkins E, Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2804–2810.)| false
• Search Google Scholar
• Export Citation

Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872–880.

• PubMed
Eifel PJ, Winter K, Morris M, Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872–880.)| false
• Search Google Scholar
• Export Citation

Stehman FB, Ali S, Keys HM, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 2007;197:503.e1–e6.

• PubMed
Stehman FB, Ali S, Keys HM, Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 2007;197:503.e1–e6.)| false
• Search Google Scholar
• Export Citation

Nam EJ, Lee M, Yim GW, et al. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013;18:843–849.

• PubMed
Nam EJ, Lee M, Yim GW, Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013;18:843–849.)| false
• Search Google Scholar
• Export Citation

Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226–1232.

• PubMed
Lorvidhaya V, Chitapanarux I, Sangruchi S, Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226–1232.)| false
• Search Google Scholar
• Export Citation

Pattaranutaporn P, Thirapakawong C, Chansilpa Y, et al. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001;81:404–407.

• PubMed
Pattaranutaporn P, Thirapakawong C, Chansilpa Y, Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001;81:404–407.)| false
• Search Google Scholar
• Export Citation

Candelaria M, Garcia-Arias A, Cetina L, et al. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15.

• PubMed
Candelaria M, Garcia-Arias A, Cetina L, Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 2006;1:15.)| false
• Search Google Scholar
• Export Citation

Christie DR, Bull CA, Gebski V, et al. Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Radiother Oncol 1995;37:181–189.

• PubMed
Christie DR, Bull CA, Gebski V, Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Radiother Oncol 1995;37:181–189.)| false
• Search Google Scholar
• Export Citation

Rakovitch E, Fyles AW, Pintilie M, et al. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:979–987.

• PubMed
Rakovitch E, Fyles AW, Pintilie M, Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:979–987.)| false
• Search Google Scholar
• Export Citation

Verma AK, Arya AK, Kumar M, et al. Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study. J Gynecol Oncol 2009;20:221–226.

• PubMed
Verma AK, Arya AK, Kumar M, Weekly cisplatin or gemcitabine concomitant with radiation in the management of locally advanced carcinoma cervix: results from an observational study. J Gynecol Oncol 2009;20:221–226.)| false
• Search Google Scholar
• Export Citation

Cerrotta A, Gardan G, Cavina R, et al. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002;23:115–119.

• PubMed
Cerrotta A, Gardan G, Cavina R, Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002;23:115–119.)| false
• Search Google Scholar
• Export Citation

Vale C, Tierney JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802–5812.

• PubMed
Vale C, Tierney JF, Stewart LA, Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802–5812.)| false
• Search Google Scholar
• Export Citation

King M, McConkey C, Latief TN, et al. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 2006;18:38–45.

• PubMed
King M, McConkey C, Latief TN, Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 2006;18:38–45.)| false
• Search Google Scholar
• Export Citation

Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer—the Addenbrooke’s experience. Clin Oncol (R Coll Radiol) 2008;20:358–364.

• PubMed
Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer—the Addenbrooke’s experience. Clin Oncol (R Coll Radiol) 2008;20:358–364.)| false
• Search Google Scholar
• Export Citation

Tabatabaei FS, Saeedian A, Azimi A, et al. Evaluation of survival rate and associated factors in patients with cervical cancer: a retrospective cohort study. J Res Health Sci 2022;22:e00552.

• PubMed
Tabatabaei FS, Saeedian A, Azimi A, Evaluation of survival rate and associated factors in patients with cervical cancer: a retrospective cohort study. J Res Health Sci 2022;22:e00552.)| false
• Search Google Scholar
• Export Citation

Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113–3119.

• PubMed
Moore DH, Blessing JA, McQuellon RP, Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113–3119.)| false
• Search Google Scholar
• Export Citation

Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626–4633.

• PubMed
Long HJ 3rd, Bundy BN, Grendys EC Jr, Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626–4633.)| false
• Search Google Scholar
• Export Citation

Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008;6:53–57.

• PubMed
Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008;6:53–57.)| false
• Search Google Scholar
• Export Citation

Tao X, Hu W, Ramirez PT, et al. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008;110 Suppl 2):S67–71.

• PubMed
Tao X, Hu W, Ramirez PT, Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008;110Suppl 2):S67–71.)| false
• Search Google Scholar
• Export Citation

Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649–4655.

• PubMed
Monk BJ, Sill MW, McMeekin DS, Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649–4655.)| false
• Search Google Scholar
• Export Citation

Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654–1663.

• PubMed
Tewari KS, Sill MW, Penson RT, Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017;390:1654–1663.)| false
• Search Google Scholar
• Export Citation

Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021;385:1856–1867.

• PubMed
Colombo N, Dubot C, Lorusso D, Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021;385:1856–1867.)| false
• Search Google Scholar
• Export Citation

Monk BJ, Colombo N, Tewari KS, et al. KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. J Clin Oncol 2023;41(Suppl):Abstract 5500.

• PubMed
Monk BJ, Colombo N, Tewari KS, KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. J Clin Oncol 2023;41(Suppl):Abstract 5500.)| false
• Search Google Scholar
• Export Citation

Regalado Porras GO, Chávez Nogueda J, Poitevin Chacón A. Chemotherapy and molecular therapy in cervical cancer. Rep Pract Oncol Radiother 2018;23:533–539.

• PubMed
Regalado Porras GO, Chávez Nogueda J, Poitevin Chacón A. Chemotherapy and molecular therapy in cervical cancer. Rep Pract Oncol Radiother 2018;23:533–539.)| false
• Search Google Scholar
• Export Citation

Boussios S, Seraj E, Zarkavelis G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol Hematol 2016;108:164–174.

• PubMed
Boussios S, Seraj E, Zarkavelis G, Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol Hematol 2016;108:164–174.)| false
• Search Google Scholar
• Export Citation

Frenel JS, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 2017;35:4035–4041.

• PubMed
Frenel JS, Le Tourneau C, O’Neil B, Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 2017;35:4035–4041.)| false
• Search Google Scholar
• Export Citation

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.

• PubMed
Marabelle A, Le DT, Ascierto PA, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.)| false
• Search Google Scholar
• Export Citation

Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929–938.

• PubMed
Maio M, Ascierto PA, Manzyuk L, Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929–938.)| false
• Search Google Scholar
• Export Citation

Cocco E, Varughese J, Buza N, et al. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer 2011;11:263.

• PubMed
Cocco E, Varughese J, Buza N, Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer 2011;11:263.)| false
• Search Google Scholar
• Export Citation

de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (innovaTV 201): a first-in-human, multicentre, phase 1–2 trial. Lancet Oncol 2019;20:383–393.

• PubMed
de Bono JS, Concin N, Hong DS, Tisotumab vedotin in patients with advanced or metastatic solid tumours (innovaTV 201): a first-in-human, multicentre, phase 1–2 trial. Lancet Oncol 2019;20:383–393.)| false
• Search Google Scholar
• Export Citation

Hong DS, Concin N, Vergote I, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 2020;26:1220–1228.

• PubMed
Hong DS, Concin N, Vergote I, Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 2020;26:1220–1228.)| false
• Search Google Scholar
• Export Citation

Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:609–619.

• PubMed
Coleman RL, Lorusso D, Gennigens C, Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:609–619.)| false
• Search Google Scholar
• Export Citation

Heitz N, Greer SC, Halford Z. A review of tisotumab vedotin-tftv in recurrent or metastatic cervical cancer. Ann Pharmacother 2023;57:585–596.

• PubMed
Heitz N, Greer SC, Halford Z. A review of tisotumab vedotin-tftv in recurrent or metastatic cervical cancer. Ann Pharmacother 2023;57:585–596.)| false
• Search Google Scholar
• Export Citation

Vergote IB, Gonzalez Martin A, Fujiwara K, et al. innovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Ann Oncol 2023;34(Suppl 2):S1276–1277. Abstract LBA9.

• PubMed
Vergote IB, Gonzalez Martin A, Fujiwara K, innovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Ann Oncol 2023;34(Suppl 2):S1276–1277. Abstract LBA9.)| false
• Search Google Scholar
• Export Citation

Oaknin A, Monk BJ, Vergote I, et al. EMPOWER Cervical-1: effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer 2022;174:299–309.

• PubMed
Oaknin A, Monk BJ, Vergote I, EMPOWER Cervical-1: effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer 2022;174:299–309.)| false
• Search Google Scholar
• Export Citation

Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544–555.

• PubMed
Tewari KS, Monk BJ, Vergote I, Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 2022;386:544–555.)| false
• Search Google Scholar
• Export Citation

Oaknin A, Monk BJ, Polastro L, et al. Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: long-term survival analysis. Ann Oncol 2022;33(Suppl 7):Abstract 519MO.

• PubMed
Oaknin A, Monk BJ, Polastro L, Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: long-term survival analysis. Ann Oncol 2022;33(Suppl 7):Abstract 519MO.)| false
• Search Google Scholar
• Export Citation

Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 Trial. J Clin Oncol 2019;37:2825–2834.

• PubMed
Naumann RW, Hollebecque A, Meyer T, Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 Trial. J Clin Oncol 2019;37:2825–2834.)| false
• Search Google Scholar
• Export Citation

Yoshimoto D, Taguchi A, Tanikawa M, et al. Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: a case enrolled in the BELIEVE trial. J Obstet Gynaecol Res 2022;48:2010–2014.

• PubMed
Yoshimoto D, Taguchi A, Tanikawa M, Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: a case enrolled in the BELIEVE trial. J Obstet Gynaecol Res 2022;48:2010–2014.)| false
• Search Google Scholar
• Export Citation

Santin AD, Deng W, Frumovitz M, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol 2020;157:161–166.

• PubMed
Santin AD, Deng W, Frumovitz M, Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol 2020;157:161–166.)| false
• Search Google Scholar
• Export Citation

Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261–1273.

• PubMed
Subbiah V, Wolf J, Konda B, Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261–1273.)| false
• Search Google Scholar
• Export Citation

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

• PubMed
Drilon A, Laetsch TW, Kummar S, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.)| false
• Search Google Scholar
• Export Citation

Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21:531–540.

• PubMed
Hong DS, DuBois SG, Kummar S, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21:531–540.)| false
• Search Google Scholar
• Export Citation

Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282.

• PubMed
Doebele RC, Drilon A, Paz-Ares L, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271–282.)| false
• Search Google Scholar
• Export Citation

Demetri GD, De Braud F, Drilon A, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 2022;28:1302–1312.

• PubMed
Demetri GD, De Braud F, Drilon A, Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 2022;28:1302–1312.)| false
• Search Google Scholar
• Export Citation

Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015;34:157–164.

• PubMed
Yan M, Schwaederle M, Arguello D, HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 2015;34:157–164.)| false
• Search Google Scholar
• Export Citation

Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59.

• PubMed
Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004;4:59.)| false
• Search Google Scholar
• Export Citation

Itkin B, Garcia A, Straminsky S, et al. Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS One 2021;16:e0257976.

• PubMed
Itkin B, Garcia A, Straminsky S, Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS One 2021;16:e0257976.)| false
• Search Google Scholar
• Export Citation

Cai ZL, Yang HT, Huang T, et al. Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials. Am J Cancer Res 2023;13:3266–3274.

• PubMed
Cai ZL, Yang HT, Huang T, Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials. Am J Cancer Res 2023;13:3266–3274.)| false
• Search Google Scholar
• Export Citation

Meric-Bernstam, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. Published online October 23, 2023. doi:10.1200/JCO.23.02005

• PubMed
Meric-Bernstam, Makker V, Oaknin A, Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. Published online October 23, 2023. doi:10.1200/JCO.23.02005)| false
• Search Google Scholar
• Export Citation